179 related articles for article (PubMed ID: 36212775)
1. Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer.
Araki H; Tazawa H; Kanaya N; Kajiwara Y; Yamada M; Hashimoto M; Kikuchi S; Kuroda S; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Mol Ther Oncolytics; 2022 Dec; 27():3-13. PubMed ID: 36212775
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
3. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
4. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
[TBL] [Abstract][Full Text] [Related]
5. Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma?
Harriss LJA; Stevens L; Rayner CJ; Simpson G; Annels NE; Frampton AE
Expert Rev Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38818792
[TBL] [Abstract][Full Text] [Related]
6. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.
Hashimoto M; Kuroda S; Kanaya N; Kadowaki D; Yoshida Y; Sakamoto M; Hamada Y; Sugimoto R; Yagi C; Ohtani T; Kumon K; Kakiuchi Y; Yasui K; Kikuchi S; Yoshida R; Tazawa H; Kagawa S; Yagi T; Urata Y; Fujiwara T
Br J Cancer; 2024 Apr; 130(7):1187-1195. PubMed ID: 38316993
[TBL] [Abstract][Full Text] [Related]
7. [Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer].
Hashimoto M; Kuroda S; Kanaya N; Kakiuchi Y; Kikuchi S; Tazawa H; Kagawa S; Urata Y; Fujiwara T
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1127-1129. PubMed ID: 36281608
[TBL] [Abstract][Full Text] [Related]
8. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
9. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
10. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
11. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
12. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
13. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer.
Koujima T; Tazawa H; Ieda T; Araki H; Fushimi T; Shoji R; Kuroda S; Kikuchi S; Yoshida R; Umeda Y; Teraishi F; Urata Y; Mizuguchi H; Fujiwara T
Mol Ther Oncolytics; 2020 Jun; 17():107-117. PubMed ID: 32322667
[TBL] [Abstract][Full Text] [Related]
15. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
16. Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer.
Tabuchi M; Kikuchi S; Tazawa H; Okura T; Ogawa T; Mitsui E; Une Y; Kuroda S; Sato H; Noma K; Kagawa S; Ohara T; Ohtsuka J; Ohki R; Urata Y; Fujiwara T
Mol Ther Oncol; 2024 Jun; 32(2):200806. PubMed ID: 38745748
[TBL] [Abstract][Full Text] [Related]
17. Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade.
Jung BK; Ko HY; Kang H; Hong J; Ahn HM; Na Y; Kim H; Kim JS; Yun CO
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753544
[TBL] [Abstract][Full Text] [Related]
18. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy.
Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Yuan YC; Liu Z; Han H; Von Hoff D; Fong Y; Woo Y
Cancer Gene Ther; 2022 Jun; 29(6):722-733. PubMed ID: 34108669
[TBL] [Abstract][Full Text] [Related]
19. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.
Tazawa H; Hasei J; Yano S; Kagawa S; Ozaki T; Fujiwara T
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085583
[TBL] [Abstract][Full Text] [Related]
20. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
